Document is current
Any future updates will be listed below
-
Authors
Kim, Dae Joong https://orcid.org/0000-0002-8646-5962
Anandh, Swetha
Null, Jamie L.
Przanowski, Piotr
Bhatnagar, Sanchita https://orcid.org/0000-0002-3588-7874
Kumar, Pankaj https://orcid.org/0000-0002-8702-8879
Shelton, Sarah E. https://orcid.org/0000-0002-9358-058X
Grundy, Erin E. https://orcid.org/0000-0001-7094-1461
Chiappinelli, Katherine B.
Kamm, Roger D. https://orcid.org/0000-0002-7232-304X
Barbie, David A.
Dudley, Andrew C. https://orcid.org/0000-0002-2663-1949
-
Funding
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (2RO1 CA177875)
American Cancer Society (129755-RSG-16-176-DDC)
- License Information
-
More Information
Article History
Received: 14 October 2021
Accepted: 30 March 2023
First Online: 14 April 2023
Competing interests
: R.D.K. is a co-founder and a board member of AIM Biotech. He also has current research support from Boehringer-Ingelheim, Roche, Amgen, GSK, and Novartis. D.A.B. reports personal fees from Qiagen, Exo Therapeutics, and Tango Biosciences; he is a Scientific Advisory Board Member/Co-Founder of XSphera Biosciences, and has received grants from Gilead, Novartis, BMS, and Lilly/Loxo Oncology. The remaining authors declare no other competing interests.
